Pharmacoeconomics of etravirine

References

• Pneumocystis pneumonia – Los Angeles. MMWR Morb. Mortal. Wkly Rep.30(21), 250–252 (1981).
   PubMedGoogle Scholar
• Hirschel B, Francioli P. Progress and problems in the fight against AIDS. N. Engl. J. Med.338(13), 906–908 (1998).
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med.338(13), 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Rietmeijer CA, Davidson AJ, Foster CT, Cohn DL. Cost of care for patients with human immunodeficiency virus infection. Patterns of utilization and charges in a public health care system. Arch. Intern. Med.153(2), 219–225 (1993).
   PubMedGoogle Scholar
• Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J. Acquir. Immune Defic. Syndr.27(1), 14–19 (2001).
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Joyce G, McCaffrey DF et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N. Engl. J. Med.344(11), 817–823 (2001).
   PubMed Web of Science ®Google Scholar
• Schackman BR, Gebo KA, Walensky RP et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med. Care44(11), 990–997 (2006).
   PubMed Web of Science ®Google Scholar
• Intelence®, prescribing information. Tibotec Therapeutics, Division of Centocor Ortho Biotech Products, Raritan, NJ (2009).
   Google Scholar
• Hall HI, Song R, Rhodes P et al. Estimation of HIV incidence in the United States. JAMA300(5), 520–529 (2008).
   PubMed Web of Science ®Google Scholar
• CDC. HIV prevalence estimates – United States, 2006. MMWR Morb. Mortal. Wkly Rep.57(39), 1073–1076 (2008).
   PubMedGoogle Scholar
• Hammer SM, Eron JJ Jr Reiss P et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society – USA panel. JAMA300(5), 555–570 (2008).
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA292(2), 191–201 (2004).
   PubMed Web of Science ®Google Scholar
• Gulick RM, Meibohm A, Havlir D et al. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS17(16), 2345–2349 (2003).
   PubMed Web of Science ®Google Scholar
• Hicks C, King MS, Gulick RM et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS18(5), 775–779 (2004).
   PubMed Web of Science ®Google Scholar
• Murphy RL, da Silva BA, Hicks CB et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naive HIV-1-infected patients. HIV Clin. Trials9(1), 1–10 (2008).
   PubMed Web of Science ®Google Scholar
• Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol.75(11), 4999–5008 (2001).
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Rohban R, Simon A et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J. Med. Virol.65(3), 445–448 (2001).
   PubMed Web of Science ®Google Scholar
• Antinori A, Zaccarelli M, Cingolani A et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res. Hum. Retroviruses18(12), 835–838 (2002).
   PubMed Web of Science ®Google Scholar
• Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet370(9581), 29–38 (2007).
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet370(9581), 39–48 (2007).
   PubMed Web of Science ®Google Scholar
• Katlama C, Haubrich R, Lalezari J et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS23(17), 2289–300 (2009).
   PubMed Web of Science ®Google Scholar
• Mills A, Cahn P, Molina J, Nij S, Vingerhoets J, Witek J. Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results. Presented at: The 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19–22 July 2009.
   Google Scholar
• Trottier B, Mills A, Cahn P et al. Durable efficacy and safety of etravirine in treatment-experienced, HIV-1-infected patients: pooled week 96 results from the Phase III DUET-1 and DUET-2 trials. Poster P148. Presented at: The 18th Annual Canadian Conference on HIV/AIDS Research. Vancouver, Canada, 23–26 April (2009).
   Google Scholar
• Eron J, Haubrich R, Reiss P et al. Clinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials. Presented at: The 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19–22 July 2009.
   Google Scholar
• Yazdanpanah Y, Fagard C, Descamps D et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin. Infect. Dis.49(9), 1441–1449 (2009).
   PubMed Web of Science ®Google Scholar
• Fagard C, Descamps D, Dubar V et al. Efficacy and safety of raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: 48-week results from the ANRS 139 TRIO trial. Presented at: The 5th IAS Conference on HIV Pathogenesis, Treatment & Prevention. Cape Town, South Africa, 19–22 July 2009.
   Google Scholar
• Nozza S, Galli L, Visco F et al. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS24(6), 924–928 (2010).
   PubMed Web of Science ®Google Scholar
• Basavapathruni A, Anderson KS. Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly. Curr. Pharm. Des.12(15), 1857–1865 (2006).
   PubMed Web of Science ®Google Scholar
• Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr. Opin. Pharmacol.4(5), 437–446 (2004).
   PubMed Web of Science ®Google Scholar
• Vingerhoets J, Tambuyzer L, Azijn H et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS24(4), 503–514 (2010).
   PubMed Web of Science ®Google Scholar
• Campbell T, Grinsztejn B, Hartikainen J, Nijs S, Witek J. Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials. Presented at: The 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 19–22 July 2009.
   Google Scholar
• Cella D, Gilet H, Viala M, Peeters K, Dubois D, Martin S. Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) questionnaire in the DUET trials. HIV Clin. Trials11(1), 18–27 (2010).
   PubMed Web of Science ®Google Scholar
• Peeters K, Viala M, Gilet H et al. Health-related quality of life (HRQL) as measured by the Functional Assessment of HIV Infection (FAHI) questionnaire in treatment-experienced HIV-1-infected patients: 24-week results from the pooled DUET trials. Presented at: The 11th European AIDS Conference. Madrid, Spain, 24–27 October 2007.
   Google Scholar
• Peterman AH, Cella D, Mo F, McCain N. Psychometric validation of the revised Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) quality of life instrument. Qual. Life Res.6(6), 572–584 (1997).
   PubMed Web of Science ®Google Scholar
• Viala-Danten M, Dubois D, Gilet H, Martin S, Peeters K, Cella D. Psychometric evaluation of the Functional Assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials. Qual. Life Res.19(8), 1215–1227 (2010).
   PubMed Web of Science ®Google Scholar
• Martin S, Hill AM. Analysis of US costs of full virologic suppression for treatment-experienced, HIV-infected patients in the DUET trials. Presented at: The XVII International AIDS Conference. Mexico City, Mexico, 3–8 August 2008.
   Google Scholar
• Gebo K, Martin S, Corbett C, DeSmedt G. Impact of etravirine on hospitalizations and hospital-related costs: 48-week findings from pooled DUET trials. Presented at: The XVIIth International AIDS Conference. Mexico City, Mexico, 3–8 August 2008.
   Google Scholar
• Stoll M, Donatz V, Corbett C, Martin S. The economic impact of national particularities in the healthcare system – calculation for hospital-related costs from pooled DUET trials by German diagnosis-related groups. Presented at: The 12th European AIDS Conference. Cologne, Germany, 11–14 November 2009.
   Google Scholar
• Martin S. Cost-minimisation analysis of two new HIV treatments for treatment-experienced patients. Presented at: The 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Athens, Greece, 8–11 November 2008.
   Google Scholar
• Hawkins N, Davies A. An indirect comparison of two new HIV treatments for treatment experienced patients. Presented at: The 30th Annual Meeting of the Society for Medical Decision Making. Philadelphia, PA, USA, 18–22 October 2008.
   Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med.359(4), 339–354 (2008).
   PubMed Web of Science ®Google Scholar
• Annemans L, Hill A, Smets E, Martin S. Cost–effectiveness of current treatment options in treatment-resistant HIV/AIDS patients in the German setting. Presented at: The 12th European AIDS Conference. Cologne, Germany, 11–14 November 2009.
   Google Scholar
• Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet369(9568), 1169–1178 (2007).
   PubMed Web of Science ®Google Scholar
• Hicks CB, Cahn P, Cooper DA et al. Durable efficacy of tipranavir–ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet368(9534), 466–475 (2006).
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med.359(14), 1429–1441 (2008).
   PubMed Web of Science ®Google Scholar
• Haubrich R, Cahn P, Grinsztejn B et al. DUET-1: week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety ofetravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients. Presented at: The 15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA, USA, 3–6 February 2008.
   Google Scholar
• Johnson M, Campbell T, Clotet B et al. DUET-2: week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients. Presented at: The 15th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA, USA 3–6 February 2008.
   Google Scholar
• Annemans L, Hill A, Smets E, Martin S, Cho M, Mrus J. Cost–effectiveness of current treatment options in treatment-resistant HIV/AIDS patients in the USA. Presented at: The American College of Clinical Pharmacy (ACCP) Spring Practice and Research Forum and Updates in Therapeutics: The Pharmacotherapy Preparatory Course. Charlotte, NC, USA, 23–27 April 2010.
   Google Scholar
• Moeremans K, Hjelmgren J, Silas M. Cost–effectiveness of etravirine in Sweden in treatment-experienced HIV-1-infected adults with evidence of NNRTI resistance and ≥3 PI mutations. Presented at: The ISPOR 12th Annual European Congress. Paris, France, 24–27 October 2009.
   Google Scholar
• Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E. Cost–effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir/ritonavir-naïve, protease inhibitor-resistant, HIV-infected adults in the UK, Belgium, Italy and Sweden. Presented at: The 9th International Congress on Drug Therapy in HIV Infection (HIV9). Glasgow, UK, 9–13 November 2008.
   Google Scholar